Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like Addex Therapeutics Shareholders Approved All Board Proposals At 2017 Annual General Meeting June 22, 2017 Auris Abandons Hearing-Loss Drug After Phase III Flop, Stock Sinks November 27, 2017 Genentech Exec Jumps Ship to Become CMO at Gritstone Oncology May 2, 2017
Addex Therapeutics Shareholders Approved All Board Proposals At 2017 Annual General Meeting June 22, 2017
